<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375959</url>
  </required_header>
  <id_info>
    <org_study_id>2010-398</org_study_id>
    <nct_id>NCT01375959</nct_id>
  </id_info>
  <brief_title>Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance</brief_title>
  <acronym>RSV</acronym>
  <official_title>The Effect of Resveratrol in Older Adults With Impaired Glucose Tolerance: a Double-Blind Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resveratrol is a substance found in many plants, including grapes and red wine, which is&#xD;
      widely used as a nutritional supplement. Studies in cells and lower animals show that&#xD;
      resveratrol has many potential benefits, including prolonging lifespan, preventing cancer and&#xD;
      heart disease and normalization of glucose metabolism. Although use of this agent shows great&#xD;
      promise in the treatment and/or prevention of diabetes, there have been no studies reported&#xD;
      to date in humans. As an initial step, this proposal is for a 6 week pilot study of&#xD;
      resveratrol treatment in older adults with impaired glucose tolerance (IGT) in order to&#xD;
      explore its effects on post-meal blood glucose metabolism. Preliminary studies will also be&#xD;
      conducted to explore how resveratrol works by studying cellular function (in muscle samples&#xD;
      obtained from study participants) and by testing resveratrol's effect on blood vessel&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A. Introduction and Specific Aims Resveratrol (RSV), a plant-derived polyphenol and potential&#xD;
      activator of the mammalian sirtuin, Sirt1, has demonstrated promising effects on insulin&#xD;
      secretion, insulin sensitivity and glucose tolerance and has extended the lifespan of obese&#xD;
      mice. RSV is in common use as a nutritional supplement, but formal studies in humans are&#xD;
      limited and-in particular-the metabolic effects of RSV in humans have yet to be carefully&#xD;
      tested. The convergence of a worldwide epidemic of diabetes combined with a marked increase&#xD;
      in the proportion of the elderly underscore the need to develop new approaches to improve&#xD;
      glucose intolerance. We therefore propose a study of RSV treatment in older subjects with&#xD;
      impaired glucose tolerance (IGT) to determine if there is improvement in glucose tolerance&#xD;
      and markers of insulin resistance, mitochondrial biogenesis and vascular function. This&#xD;
      proposal builds on our findings in a recently-completed NIH P01 on cardiovascular disease&#xD;
      markers in older adults with IGT. It is our hypothesis that RSV has the potential to exert&#xD;
      important metabolic effects that can be directly and safely tested in human subjects. The&#xD;
      growing body of pre-clinical evidence, as well as our own preliminary data, provide strong&#xD;
      support for formal tests of RSV effects on several important metabolic parameters. These&#xD;
      proposed studies constitute a critical step in investigating the therapeutic potential of&#xD;
      RSV, as well as providing insight into relevant mechanisms.&#xD;
&#xD;
      Specific Aims: We propose a 6-week randomized, double-blind, placebo controlled cross-over&#xD;
      study of RSV in older adults (age 50-80 years, n=38) with IGT, with the following aims:&#xD;
&#xD;
      Specific Aim 1: To assess the effects of RSV (2g/day) on mixed meal tolerance in subjects&#xD;
      with age-related glucose intolerance. In our previous studies, we developed a standard mixed&#xD;
      meal protocol to evaluate postprandial changes in glucose, insulin and lipids. We will apply&#xD;
      this protocol to study a cohort of older adults with impaired glucose tolerance in a&#xD;
      double-blind, placebo controlled cross-over study of RSV treatment. Metabolic outcomes will&#xD;
      include post-meal glucose area under the curve (AUC), calculated estimates of insulin&#xD;
      sensitivity and insulin secretion and circulating levels of free fatty acids and&#xD;
      triglycerides. This study will be the first to document RSV effects on glucose intolerance in&#xD;
      humans and will provide critical information needed to inform future clinical and mechanistic&#xD;
      investigations. We hypothesize that treatment with RSV will result in improvement in mixed&#xD;
      meal tolerance, via effects on insulin secretion, insulin action or both, in subjects with&#xD;
      age-related glucose intolerance.&#xD;
&#xD;
      Specific Aim 2: To assess the effects of RSV on age-related decline in mitochondrial&#xD;
      biogenesis. In animal models, RSV has been shown to enhance mitochondrial biogenesis, which&#xD;
      may occur through activation of Sirt1, which is an important regulator of cellular energy&#xD;
      metabolism via PGC-1Î±. We will assess this directly by measuring mitochondrial mRNA&#xD;
      expression and DNA copy number in muscle obtained from participants after treatment with RSV&#xD;
      compared with placebo. Studies of mitochondrial morphology and enzyme activity will be&#xD;
      performed in collaboration with Dr. Sreekumaran Nair (Mayo Clinic), who is an expert in&#xD;
      mitochondrial physiology. We hypothesize that treatment with RSV will result in improvement&#xD;
      in mitochondrial number and function, which is a potential mechanism for improvement in&#xD;
      insulin sensitivity that may occur with RSV treatment.&#xD;
&#xD;
      Specific Aim 3: To assess the effects of RSV on fasting and post-meal endothelial function.&#xD;
      Since treatment with RSV has also been reported to have beneficial cardiovascular effects,&#xD;
      including improved vascular reactivity, we will study in vivo endothelial function. We will&#xD;
      use reactive hyperemia peripheral arterial tonometry to assess endothelial dependent&#xD;
      vasodilation in study subjects before and after treatment with RSV, in both the fasting and&#xD;
      postprandial state. Augmentation index, a measure of arterial stiffness will also be&#xD;
      assessed. We hypothesize that chronic treatment with RSV will result in improvement in&#xD;
      endothelial function through direct vascular effects, which may be mediated via enhanced&#xD;
      nitric oxide availability, reduced oxidative stress and/or as a consequence of improvement in&#xD;
      glucose metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Meal Glucose Area Under the Curve</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
    <description>Glucose AUC following a standard mixed meal challenge AUC, Area Under a Curve. There are no &quot;normal ranges&quot; but a higher value is worse than a lower value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
    <description>Matsuda index and HOMA-IR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
    <description>c-peptide deconvolution; HOMA-B</description>
  </other_outcome>
  <other_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
    <description>reactive hyperemia peripheral arterial tonometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene Expression Profile</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
    <description>gene expression in skeletal muscle using RNASeq</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>resveratrol 500 mg capsules, 3 each day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo capsule containing lactose, 3 each day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>resveratrol</intervention_name>
    <description>resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <other_name>RevGenetics</other_name>
    <other_name>X500 Resveratrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 placebo capsules orally twice a day for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  impaired glucose tolerance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of estrogen-dependent neoplasm&#xD;
&#xD;
          -  use of certain drugs: high dose statins, warfarin, antiepileptics&#xD;
&#xD;
          -  current treatment with anti-diabetes medications&#xD;
&#xD;
          -  impaired liver or kidney function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine of Yeshiva University</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <results_first_submitted>January 2, 2018</results_first_submitted>
  <results_first_submitted_qc>August 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Jill Crandall</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>resveratrol</keyword>
  <keyword>glucose intolerance</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Resveratrol First, Then Placebo</title>
          <description>resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks&#xD;
wash-out period for 2 weeks&#xD;
matching placebo capsule containing lactose, 3 orally twice a day for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Resveratrol</title>
          <description>matching placebo capsule containing lactose, 3 orally twice a day for 6 weeks&#xD;
wash-out period for 2 weeks&#xD;
resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Invertention</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">Two participants were withdrawn due to adverse events.</participants>
                <participants group_id="P2" count="18">Three participants were withdrawn due to adverse events.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Wash-Out (3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Resveratrol First</title>
          <description>resveratrol 500 mg capsules, 3 each day for 6 weeks&#xD;
resveratrol: resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo First</title>
          <description>matching placebo capsule containing lactose, 3 each day for 6 weeks&#xD;
Placebo: 3 placebo capsules orally twice a day for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="8"/>
                    <measurement group_id="B2" value="67" spread="6"/>
                    <measurement group_id="B3" value="67" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Meal Glucose Area Under the Curve</title>
        <description>Glucose AUC following a standard mixed meal challenge AUC, Area Under a Curve. There are no &quot;normal ranges&quot; but a higher value is worse than a lower value.</description>
        <time_frame>end of each of two 6 week treatment periods</time_frame>
        <population>Out of 38 total randomized, 35 actually received resveratrol and 36 actually received placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Resveratrol</title>
            <description>Participants received resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo, 3 capsules (matching placebo capsule containing lactose), orally twice a day for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Post Meal Glucose Area Under the Curve</title>
          <description>Glucose AUC following a standard mixed meal challenge AUC, Area Under a Curve. There are no &quot;normal ranges&quot; but a higher value is worse than a lower value.</description>
          <population>Out of 38 total randomized, 35 actually received resveratrol and 36 actually received placebo.</population>
          <units>mg*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508" spread="88"/>
                    <measurement group_id="O2" value="513" spread="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>Matsuda index and HOMA-IR</description>
        <time_frame>end of each of two 6 week treatment periods</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Insulin Secretion</title>
        <description>c-peptide deconvolution; HOMA-B</description>
        <time_frame>end of each of two 6 week treatment periods</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Endothelial Function</title>
        <description>reactive hyperemia peripheral arterial tonometry</description>
        <time_frame>end of each of two 6 week treatment periods</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gene Expression Profile</title>
        <description>gene expression in skeletal muscle using RNASeq</description>
        <time_frame>end of each of two 6 week treatment periods</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During full 16 week study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Resveratrol</title>
          <description>resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo capsule containing lactose, 3 orally twice a day for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>hospitalized for bronchitis and pneumonia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal electrocardiogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal liver function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated PSA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jill Crandall</name_or_title>
      <organization>Albert Einstein College of Medicine</organization>
      <phone>718-430-3765</phone>
      <email>jill.crandall@einstein.yu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

